Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 2Phase 1 2

Status

Completed 8Recruiting 3Active not recruiting 3Withdrawn 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 20venetoclax 19Radiotherapy 19Gemcitabine 19Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12Azacitidine 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × polatuzumab vedotin × Clear all
NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 1/2 Active not recruiting
211 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03671018 2024-11-29

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1/2 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, B-Cell

NCT04914741 2024-08-12

COALITION

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
80 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡